Sandbox
The U.S. Food and Drug Administration has issued a formal warning letter to Genzyme Ireland Limited, the Waterford-based subsidiary of French pharmaceutical giant Sanofi, citing "significant" violations of current good manufacturing practice (CGMP) regulations at the facility. The warning letter, dated June 22, 2026, follows an FDA inspection conducted at the Waterford site in January 2026 and targets manufacturing processes linked to the haemophilia A therapy Altuviiio and the immunosuppressant Thymoglobulin.
The action marks a significant regulatory blow for one of Ireland's most prominent pharmaceutical manufacturing operations, and the second warning letter Sanofi has received from the FDA in less than 18 months — a pattern that will invite intense scrutiny of the company's quality management systems globally.
What the FDA Found
The FDA's inspection, conducted between January 12 and January 20, 2026, uncovered a cluster of systemic failings at the Waterford facility. Inspectors documented concerns across three principal areas:
1. Data Integrity Failures
The most damaging finding relates to data integrity — the bedrock of any CGMP-compliant manufacturing operation. FDA investigators concluded that the site's data integrity programme was not functioning as represented to regulators. Specifically, inspectors found that quality control personnel had been using uncontrolled Review Checklists — informal, off-system documents used to track laboratory record reviews — which were subsequently discarded rather than retained as required under federal regulations.
In pharmaceutical manufacturing, every step, review, and decision must be traceable to a named individual and time-stamped in controlled systems. The FDA noted that record updates were not always attributable to a specific person, undermining the facility's ability to demonstrate who reviewed what, and when — a fundamental failure of traceability that regulators treat with particular seriousness.
2. Cancelled Deviations Without Proper Investigation
Inspectors also found evidence of systemic under-investigation of quality events. The warning letter identifies a pattern of "cancelled deviations" — instances where quality-related anomalies or departures from expected manufacturing standards were formally logged but then closed without proper investigation or assessment of whether the event had any impact on product quality or patient safety.
Even after Sanofi conducted a retrospective review of these cancelled events in response to inspector queries, the FDA concluded that the company's justifications for why the deviations did not affect product quality were inadequate. This is a significant finding: it suggests that not only were events improperly closed initially, but that even on reflection, Sanofi was unable to provide satisfactory scientific rationale for its decisions.
3. Failure of the Quality Unit to Exercise Proper Oversight
Underpinning both of the above findings is a broader conclusion from the FDA: the site's quality unit failed to exercise adequate oversight of manufacturing operations. Under CGMP rules, the quality unit — akin to an internal regulator within the plant — must independently oversee all production activities and have the authority and capability to identify, investigate, and resolve quality issues. The FDA's assessment suggests that this fundamental safeguard was not operating effectively at the Waterford site.
Products Affected: Altuviiio and Thymoglobulin
Altuviiio (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl) is Sanofi's flagship recombinant clotting factor therapy for adults and children with Haemophilia A — a rare, life-threatening bleeding disorder caused by a deficiency in Factor VIII. Approved by the FDA in February 2023, Altuviiio was a significant commercial launch for Sanofi, offering an extended half-life that allows for less frequent dosing than earlier Factor VIII therapies. It is administered intravenously and is a critical, life-sustaining medication for many patients.
The Waterford facility's manufacturing role in producing Altuviiio makes the quality concerns particularly significant from a patient safety standpoint — although the FDA has not, at this stage, indicated any specific product quality risk or ordered a recall.
Thymoglobulin (Anti-thymocyte Globulin [Rabbit]) is an immunosuppressant used to prevent organ rejection in kidney transplant patients and to treat aplastic anaemia. Like Altuviiio, it is a specialised therapy with no simple substitute, giving the Waterford site considerable strategic importance within Sanofi's global manufacturing network.
Note: This warning letter is distinct from a separate Altuviiio recall in February 2025, which related to erroneous dose potency labelling on a single lot (lot #EY0330) and was unconnected to the current CGMP concerns.
Sanofi's Response
Sanofi has acknowledged the warning letter and struck a conciliatory tone in its public response. A company spokesperson stated that Sanofi takes the warning letter with the "utmost seriousness" and is committed to addressing each of the FDA's observations in a "robust and sustainable" manner.
Crucially, Sanofi has indicated that it does not expect the warning letter to impact drug supplies from the Waterford facility. Warning letters, while serious regulatory actions, do not automatically trigger a manufacturing shutdown or supply disruption — but they do invite heightened scrutiny and typically require companies to submit detailed corrective and preventive action (CAPA) plans to the FDA within a defined timeframe.
Context: A Second Warning in 18 Months
The Genzyme Ireland warning letter comes approximately 18 months after a separate FDA warning letter issued in January 2025, which targeted Sanofi's manufacturing facility in Framingham, Massachusetts, citing contamination-related and quality control failures at that site. That earlier action — also linked to Altuviiio production — raised questions about whether Sanofi's manufacturing quality systems were keeping pace with its commercial ambitions.
Two warning letters across two facilities in such a short period will inevitably prompt questions about the adequacy of Sanofi's global manufacturing governance framework. Regulators, analysts, and investors will be watching closely to see whether the company's CAPA commitments translate into verifiable, durable improvements — or whether further regulatory actions follow.
Ireland's Pharma Sector Under the Microscope
Ireland hosts some of the world's most significant pharmaceutical manufacturing infrastructure, with nine of the world's ten largest pharma companies operating on the island. The Waterford region — home to several life sciences facilities — has long been a cornerstone of the south-east's industrial economy.
While a single FDA warning letter does not reflect on Ireland's broader manufacturing standards, it will nonetheless attract attention at a time when global regulators are intensifying scrutiny of CGMP compliance and data integrity across the industry. The Irish Health Products Regulatory Authority (HPRA), which co-regulates pharmaceutical manufacturing in Ireland alongside the EMA and FDA, will likely monitor Sanofi's remediation progress closely.
What Comes Next
Under standard FDA procedure, Genzyme Ireland Limited is required to respond formally to the warning letter within 15 business days, detailing the corrective actions it will take — and has already taken — to address each cited violation. The FDA will evaluate those commitments and, typically, conduct a follow-up inspection to verify that the remedial measures have been implemented effectively before considering the matter resolved.
Until the warning letter is formally closed, the Waterford facility will remain subject to elevated regulatory attention. In practical terms, this can affect new product approvals tied to the site and may complicate Sanofi's regulatory interactions across other markets that recognise FDA inspections as a benchmark.
For Sanofi, the path forward is clear if not easy: transparency, rapid and documented corrective action, and a demonstration that the data integrity and quality oversight failures identified by inspectors represent a closed chapter — not a persistent pattern.
